Heartburn, Gastroesophageal Reflux Disease
Key facts
- Who runs it
- Incheon St.Mary's Hospital
- Where
- South Korea10 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 160 people, planned
- Started
- 7 Jul 2025
- Planned end
- 30 Sept 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Zastaprazan
- Esomeprazole
- Record updated
- 23 December 2025
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Korean adults aged 19 years or older as of the date of written consent
- Those diagnosed with erosive gastroesophageal reflux disease based on upper gastrointestinal endoscopy (EGD)
- Those who reported nighttime heartburn for more than 3 months at the time of screening (Visit 1)
- Those who voluntarily decided to participate and provide written informed consent
Who cannot take part
- Individuals who have received other investigational products within one month prior to the screening visit (Visit 1)
- Individuals with a history of drug or alcohol abuse (within the past year)
- Those who cannot undergo upper gastrointestinal endoscopy (EGD)
- In addition to the above, individuals with clinically significant findings that the investigator deems medically inappropriate for the present study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Gastroesophageal reflux disease (GERD) is a condition caused by the reflux of stomach contents into the esophagus, presenting with typical symptoms such as heartburn and acid regurgitation.
Read full original descriptionShow less
GERD is a chronic condition that affects quality of life, and patients with this condition are known to have a lower quality of life compared to healthy individuals. In particular, nocturnal heartburn can lead to sleep deprivation and affect daily life, as well as overall quality of life.
This study aims to evaluate the efficacy of alleviating nocturnal heartburn symptoms in patients with erosive reflux disease (ERD).
The 2 groups in the trial
- ZastaprazanTreatment being tested
Zastaprazan 20 mg, once daily, preferably administered orally in the morning before breakfast for four weeks
- EsomeprazoleExisting treatment, for comparison
Esomeprazole 40 mg, once daily, preferably administered orally in the morning before breakfast for four weeks
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Double-blind, Randomized, Investigator-initiated Trial to Evaluate the Degree of Symptom Relief of Zastaprazan and Esomeprazole in Patients With Erosive Reflux Disease With Night-time Heartburn Symptoms
- Record updated
- 23 December 2025